Login to Your Account

Mologen shares rise on MGN1703 survival data in CRC patients

By Cormac Sheridan
Staff Writer

Tuesday, July 1, 2014
Shares in Mologen AG rose 13 percent Monday on interim survival data indicating that a small subgroup of patients with metastatic colorectal cancer experienced lengthy – and ongoing – progression-free survival (PFS) with cancer immunotherapy MGN1703.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription